Feedback / Questions
lixudebart (ALE.F02) - Alentis Therap
https://www.businesswire.com/multimedia/molecularlab/20240529924263/en/5658495/Alentis-Receives-FDA-Orphan-Drug-Designation-for-Lixudebart-to-Treat-Idiopathic-Pulmonary-Fibrosis
May 29, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next